FBIOP Latest Press Releases

-- March 31, 2026 --

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights Globe Newswire 4:05 PM

-- March 30, 2026 --

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million Globe Newswire 4:05 PM

-- February 23, 2026 --

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million Globe Newswire 9:24 AM

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million Globe Newswire 8:30 AM

-- January 13, 2026 --

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Globe Newswire 7:45 AM

-- December 15, 2025 --

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software